Delcath Systems, Inc. (NASDAQ: DCTH), a medical technology company specializing in cancer treatment, is currently testing a proprietary, patented drug delivery system designed to treat liver cancers. The company is enrolling patients in Phase III and Phase II clinical studies for the treatment of liver cancers using high doses of melphalan. Twenty-eight international patents consist of the Company’s intellectual property portfolio. For further information, visit the Company’s web site at www.delcath.com.
Delcath Systems, Inc. (NASDAQ: DCTH)
November 3, 2008 at 5:47am
Archives
Select A Month
